Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02459587 · ClinicalTrials.gov registry record · NA

Crisis Line Facilitation

A NA study, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
307
Enrollment target

NCT02459587: Completed NA study, sponsored by VA Office of Research and Development.

NCT02459587 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 307 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02459587, a NA study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
307 participants
Enrollment target

Study Summary

This study is a randomized controlled trial (n = 301) of a new single-session intervention, called Crisis Line Facilitation (CLF), compared to an enhanced usual care condition on utilization of the Veterans Crisis Line and other mental health services as well as suicide attempt(s). All participants were recruited during an inpatient psychiatric stay for the treatment of a recent suicidal crisis and will be re-assessed at 3-, 6- and 12-months post baseline. If successful, the proposed study will provide key data on the potential efficacy of a brief tool to improve the utilization of an existing resource, the Veterans Crisis Line, to reduce suicidal behaviors in VHA patients.

Primary Outcome

The primary data source for information regarding use of the VCL was collected via researcher-administered interview questions during the TimeLine Follow Back assessment. Participants were asked to recall how many times since the last assessment in which they contacted the VCL for any reason. For contacts that occurred, participants were asked to recall the date of these contacts and the type of contact that was made (e.g. phone call, text, or chat).

Interventions

  • BEHAVIORAL Enhanced Usual Care (EUC)
  • BEHAVIORAL Crisis Line Facilitation (CLF)

Trial Details

FieldValue
Enrollment Target 307 participants
Start Date 2016-03-24
Est. Completion 2019-12-11
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT02459587 record still lists

NCT02459587 is an interventional study that assigns participants to a tested intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which Enhanced Usual Care (EUC) is the first listed.

NCT02459587 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02459587 about?

NCT02459587 is a clinical study titled "Crisis Line Facilitation". This study is a randomized controlled trial (n = 301) of a new single-session intervention, called Crisis Line Facilitation (CLF), compared to an enhanced usual care condition on utilization of the Veterans Crisis Line and other mental health services as well as suicide attempt(s). All participants ...

What is the current status of trial NCT02459587?

This trial is currently completed. It is a NA study. The enrollment target is 307 participants. The study started on 2016-03-24. Estimated completion is 2019-12-11.

What interventions are being tested in trial NCT02459587?

The interventions under investigation include: Enhanced Usual Care (EUC) (BEHAVIORAL), Crisis Line Facilitation (CLF) (BEHAVIORAL).

Who is sponsoring clinical trial NCT02459587?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02459587's enrollment target sits among peer trials

307 324th of 2000 higher than 1,677 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05433142 · 307 participants · Phase 1

    Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • NCT04162938 · 308 participants · NA

    Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum

  • NCT04955795 · 308 participants · NA

    Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA

  • NCT06090539 · 308 participants · Phase 1

    A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02459587, the US trial registry maintained by the National Library of Medicine. NCT02459587 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.